Products
Platform
Research
Market
Learn
IPO
Compare Kotak Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.34 | 1.86 |
NAV | ₹13.47 | ₹40.22 |
Fund Started | 20 Nov 2023 | 25 Jun 2018 |
Fund Size | ₹481.04 Cr | ₹6437.36 Cr |
Exit Load | 0.5% for redemption within 30 Days | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.34
1.86
NAV
₹13.47
₹40.22
Fund Started
20 Nov 2023
25 Jun 2018
Fund Size
₹481.04 Cr
₹6437.36 Cr
Exit Load
0.5% for redemption within 30 Days
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | -3.48% | 3.63% |
3 Year | - | 26.54% |
5 Year | - | 19.11% |
1 Year
-3.48%
3.63%
3 Year
-
26.54%
5 Year
-
19.11%
Holding Analysis
Equity | 98.71% | 97.10% |
Cash | 1.29% | 2.90% |
Equity
98.71%
97.10%
Cash
1.29%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.36% |
Max Healthcare Institute Ltd. | 7.75% |
JB Chemicals & Pharmaceuticals Ltd. | 5.63% |
Divi's Laboratories Ltd. | 5.60% |
Cipla Ltd. | 4.68% |
Fortis Healthcare Ltd. | 4.25% |
Apollo Hospitals Enterprise Ltd. | 4.23% |
Lupin Ltd. | 3.88% |
Acutaas Chemicals Ltd. | 3.23% |
Jubilant Pharmova Ltd. | 3.20% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Shibani Sircar Kurian | Dharmesh Kakkad |
Start Date | 12 Feb 2024 | 23 Feb 2021 |
Name
Shibani Sircar Kurian
Dharmesh Kakkad
Start Date
12 Feb 2024
23 Feb 2021
About Fund
Description | The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 20 Nov 2023 | 25 Jun 2018 |
Description
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
20 Nov 2023
25 Jun 2018